IQVIA Launches Patient Portal to Transform the Clinical Trial Experience

Aug 15, 2019

DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA™ (NYSE:IQV) announces its launch of the IQVIA Patient Portal, a global web-based solution built on a leading health cloud platform. This innovative tool enables increases in clinical trial patient recruitment, engagement and retention by ensuring transparency and collaboration before, during, and after a clinical study.

“Patient communities are clear about what matters most to them, roughly 90 percent want access to information about their participation in the study including updates about the outcome of a study,” said Cynthia Verst, president, Design and Delivery Innovation, Research & Development Solutions at IQVIA. “IQVIA’s Patient Portal increases patient understanding and engagement during the trial and reduces the substantial cost associated with patients dropping out of a trial or being unavailable for follow-up.”

Trial participants are invited to join the IQVIA Patient Portal when they are recruited. Upon enrollment, they are guided through the trial process with study visit and medication reminders, disease education, and concierge and travel support services. In addition, they are provided access to the individual lab results from their participation and other general information relating to the study as approved by the sponsor and investigator. Upon trial completion, patients receive a plain language summary of the study. Additionally, patients can join an alumni community where they can continue to engage with clinical research through future trial participation opportunities.

IQVIA’s geographic scale and expertise address the regulatory and compliance needs of customers regardless of where the study takes place, and retention solutions are built specifically for each clinical trial location with relevant study-level content.

The IQVIA Patient Portal is part of IQVIA’s full-service clinical trial offering or as a stand-alone solution. For more information about the IQVIA Patient Portal, visit www.iqvia.com.

About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies Human Data Science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 61,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Click here to subscribe to Mobile Alerts for IQVIA.

Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.

Media Inquiries

Please use this form to reach out to our media team with inquiries. Thank you.